Children's Hospital is part of the UPMC family.
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Ranked #8 Nationally by U.S. News & World Report.
Can you name a disease that you cared for where inflammation is not one of the major things driving that disease? Scott Canna, MD, rheumatologist at UPMC Children’s Hospital and a Mellon Scholar with the Richard King Mellon Foundation Institute for Pediatric Research, asks our hosts this question and talks about modulating our immune system in both rare and common diseases. Dr. Canna has been actively researching ways to better understand and treat inflammatory disorders for over a decade.
View the transcript in a new window (PDF)
Steph Dewar: This podcast is for informational and educational purposes only and is not to be
considered medical advice for any particular patient. Clinicians must rely on
their own informed clinical judgments when making recommendations for their
patients. Patients in need of medical advice should consult their personal
John Williams: From UPMC Children's Hospital of Pittsburgh, welcome to That's Pediatrics. I'm
your host, John Williams from the Division of Pediatric Infectious Diseases.
Steph Dewar: And I'm Steph Dewar, Residency Program Director and a member of the
John Williams: And we are delighted to welcome our guest today, Dr. Scott Canna. Dr. Canna is
a board certified Pediatric Rheumatologist. He sees children with general
pediatric rheumatology diseases and inflammatory diseases in the outpatient
clinic of the division of rheumatology at UPMC Children's Hospital of Pittsburgh.
His research focuses on auto-inflammation in advancing both the science and
clinical practice of immune dysregulation. Scott, welcome to That's Pediatrics.
Scott Canna: Thanks very much for having me.
Steph Dewar: Well, we're excited to have you here today and to hear about the types of
patients that you're caring for, and the types of science that you're doing here
Scott Canna: I've been here for about two years. And the reason I bring that up is because the
types of patients I see were greatly informed by where I came from. And so I
was at the NIH for four years before coming here, seeing these patients with
what we call auto-inflammatory diseases. And it's a little bit of a category of
exclusion. So first I like to put people on the spot. So name a disease that you
care for where inflammation is not one of the major most important things that
is driving that disease.
Steph Dewar: Oh, that's such a great question. Let's think about that now.
John Williams: Where it's inflammation is not one of the major. Oh, I'm
Steph Dewar: Traumatic brain injury.
Scott Canna: Oh, that's definitely way wrong. Trauma, that you release all these damage
associated molecular patterns. Yeah, I think that you're throwing yourself under
the bus there. So
John Williams: I'm an infectious disease doctor, so I'm just going to give up right now and say, I
think for me it's all inflammation.
Scott Canna: So I like to tell every other specialist that what they like best about their job is
every day at my job. So we study inflammation. So obviously if you're infected, if
you've had trauma, even if you have cancer or practically every other situation
in the hospital from asthma, even to after the acute phase of epilepsy,
inflammation is a major part of the problem.
So we try to go, the other part of the problem is that inflammation is really
complex. And sort of the best example of that is the fact that we don't usually
go after the inflammatory part of a lot of the diseases that we treat because we
don't understand it very well. It's 2018 and we're still giving lots of steroids for
asthma. Can we do better? Sure. But it's complex. So around the turn of the
century, there was this sort of correlation of learning more about basic
inflammation and having the genetic tools to figure out the underlying causes
for some rare inflammatory diseases.
The first of these was called Familial Mediterranean Fever, FMF. And we figured
out the gene for that. And that explained a little bit of what was causing that
disease. And what was causing that disease wasn't infection, it wasn't cancer, it
wasn't trauma. And it wasn't classical autoimmunity where we think of autoantibodies and loss of tolerance to T-cells. It was actually sort of a hyper
activation of our inflammatory system, our innate immune system.
And so that spawned this whole field of auto-inflammation. And so the bread
and butter of the research that I've done since 2005 has been trying to connect
the dots between some of these genetic diseases that we've discovered in these
patients, and then why they get sick, and how they get sick. And that's been
really interesting in understanding human biology in those rare patients. But it's
also had a lot of just sort of spreading effects into how we understand
inflammation in practically every patient that comes into the clinic.
Steph Dewar: So that is such an interesting thing that you said about steroids and asthma, as
somebody who went to medical school several decades ago. I know that we
know way more about inflammatory response these days. But the truth of the
matter is when I give patients with asthma systemic steroids, they improve. And
also when I give them a controller, which is an inhaled daily steroid, they tend to
have less acute episodes. So how does what you're talking about translate to
what I'm doing? Because I feel as though sometimes our body's natural
response of inflammation actually makes us a little worse.
Scott Canna: Oh, absolutely. I mean, as probably one of the biggest purveyors of steroids in
the hospital, rheumatologists love to use steroids. But it's a bit of a blunt
instrument. And so absolutely, asthma is an inflammatory disease. And I don't
think anybody would disagree with that. But what do we mean by
inflammation? And can we do something better than steroids?
And certainly lots and lots of very bright people at this institution and elsewhere
are trying. But it's been a tough nut to crack because inflammation's so
complex. But those same patients that you're giving all those steroids to, they
get infections because the blunt instrument of steroids is immunosuppressive.
They don't grow very well because steroids have all kinds of awful side effects.
And so can we do better? Absolutely. And in fact, there's a lot on the hot ... I
don't want to spend this whole time talking about asthma.
But just as an example of a disease that every of us has treated 1,000 times
where our immunologic understanding of it in the lab seems to be way beyond
what we're doing in the clinic in a targeted fashion. And that's where some of
these genetic insights have been really helpful in not just narrowing down the
pathology, but sort of pointing with a big sort of blinking finger to say this is the
place where you want to intervene, that's the place where you're going to fix all
John Williams: So you mentioned, Scott, and I want to hear in a second about what blinking
arrows you've been seeing and following, but you really highlighted the
difference between a classic autoimmune disease where the adaptive immune
system, T cells, B cells, et cetera, attack tissues like Lupus or Rheumatoid
Arthritis, and what you're calling innate, problems with the innate immune
system. Are there a lot of diseases in that bucket? And do they collectively sort
of add up to a lot of suffering in kids?
Scott Canna: Yeah, absolutely. So I think any distinction that you make in immunology is kind
of arbitrary by definition because all of these systems interact. But the current
best way that we parse the immune system's response is between innate and
adaptive immunity. And innate immunity is sort of the more ancient version of
our immune system.
And that includes things like barriers like our skin, and our gut, and some of the
things that our skin and our gut make to keep those barriers intact. And then
the really rapid, often really robust, but often really damaging inflammatory
responses that happen really quick but not in a very adaptive way that they
don't tailor themselves to one specific antigen or one specific bug.
So among the more common diseases, I would say that any disease where
there's a substantial amount of inflammation where we don't think that it's an
autoimmune disease, probably has a pretty big auto-inflammatory component.
Probably the most accessible one is gout, where gout is this massive
inflammatory response to these weird crystals. And we now know that those
crystals trigger this innate immune complex called the NLRP3 inflammasome.
And because of the diseases that are associated with the NLRP3 inflammasome,
that pointed to this one very specific molecule called IL1, and if you block IL1 in
patients that have a mutation NLRP3, it's magical. And if you block IL1 in Gout,
it's pretty magical.
It's not first line treatment because it's also pretty expensive, and you'd like to
prevent gout episodes by preventing what triggers that innate immune attack.
But I would say that sort of disease burden of auto-inflammation written large is
really broad. Obviously disease burden of these really rare genetic diseases is
not super broad. But the things that they teach us and the mechanisms that
they point out, as I said, are pretty broad.
Steph Dewar: So can you talk to us a little bit about the research that you're involved with
here at Children's?
Scott Canna: Sure, I would love to. So, I love my job. I get to come into lab and we try to ask
really important, interesting and hard questions every day and use the best
tools that we can. Luckily we're in a place like Pittsburgh where all those tools
are available to us, to answer those questions in a way that's clinically
And so to me, that's sort of how I define translational research, is that the
experiments that you do day in and day out are guided by things that are
clinically meaningful. And so that's a little bit broad, but that's kind of where we
bring it in. So I've been interested in auto-inflammatory diseases for a very long
time. And then when I did my fellowship, I got really interested in some of
diseases that weren't clearly auto inflammatory, that looked kind of like sepsis
only without the infection.
So patients who were just unbelievably ill in our intensive care unit, what we
might call hyper-inflammatory, often they have really high serum ferritin levels.
So sometimes they get called hyperferritinemic. And what was kind of
conspicuous is that we had been following what started as a few and are now
dozens of genetic auto-inflammatory diseases.
And by and large, when you looked across all of these people who we knew had
a genetically encoded increase in their innate immune system, they didn't get
septic. They didn't get this sort of systemic inflammatory phenotype that ended
up in the ICU. And so I got interested in a disease that we see in rheumatology
called macrophage activation syndrome, which is just one of the names we give
to this hyper-inflammation phenotype. And while I was at the NIH, we started
bringing in some of these patients and doing what we do, the genetics on them.
And we found, low and behold, a genetic mutation in a gene called NLRC4,
which is also a driver of this inflammasome. And it was kind of a big deal
because this was the first known sort of auto-inflammatory genetic cause of
something that looked like a hyper-inflammatory sepsis. So what's really great
about working in the auto-inflammatory field is that everybody wants to use the
work of everyone else to try and understand what makes diseases different.
And so because I'd been studying inflammasome problems for so long, we were
able to compare these new patients with this NLRC4 problem with other
patients that we knew had inflammasome problems, but had a totally different
phenotype, at least to people who look only at inflammation. And what really
stood out was this other molecule called interleukin 18, or IL 18. And so that has
become one of the cornerstones of what our lab works on now, is trying to
understand what's unique about IL 18, and why does it seem to predispose
people to this really horrible phenotype called Macrophage Activation
John Williams: So some patients, all of these are patients who have mutations in these innate
immune responses. But it sounds like what you're saying is only a subset
develop this severe systemic overwhelming inflammation, and that's mainly
driven by IL 18?
Scott Canna: Yeah. So we think that IL 18 is one of the mechanisms, because of genetic work
that was done long before I got into science. We know another mechanism
actually has to do with killer cell function. So part of our immune system
includes these killer cells. We have natural killer cells and we have cytotoxic T
cells. And they're called killers because they kill through this granule mediated
And so if you have a genetic problem in killing, you get a very similar phenotype.
And so we're trying to, actually, it's one of the projects we're working very
closely on right now, is figure out how do you get to the same horrible systemic
inflammatory phenotype from these two very different mechanisms of killing
problems or excess IL 18? Is it all one thing that converges somewhere
upstream of that disease? Or do they get there from totally different
And the relevance here is that IL 18 and killer cell function are things that are
variable in the population in general. And so just because we use these genetic
diseases as kind of what I'll call inflammatory archetypes, they define a very
pure and very sort of clean mechanism of disease. But that tells you what kinds
of mechanisms you should be looking in patients where you don't have a
genetic cause. And that's where we've tried to build in a lot of biomarker
discovery, to say, "What are the biomarkers of our inflammatory archetypes?
And then how do they function, those biomarkers? What do they look like in our
patients who we don't have any genetic reason to think that they have a
Steph Dewar: So what I think I hear you saying is pursuing this line of inquiry could potentially
allow us to better understand what child is more at risk for this type of
response, and potentially intervene and prevent that?
Scott Canna: Absolutely. And I mean we've been doing this since the beginning of things. So
when we first found some of these auto-inflammatory diseases, and we saw this
dramatic response of blocking IL 1 in those inflammatory diseases, we said,
"Well, we have a whole bunch of other patients. We don't know what their
genetic problems are, but because of their clinical description, or because of
these biomarkers, they look similar to these genetic patients. Let's try blocking
IL 1 in them."
And bam, it's been revolutionary. And so now we're blocking IL 1 in all kinds of
diseases that we wouldn't necessarily have ever gotten to if we hadn't studied
these rare genetic diseases so closely. And so we're doing the same thing now
with IL 18 in sort of a later generation.
Steph Dewar: Are there unintended consequences? It seems as though this is a body's
response. Are you modulating it or shutting it down?
Scott Canna: So of course I have a response to this.
John Williams: An inflammatory response?
Scott Canna: Well, depending on who you ask, all of my responses are inflammatory. So, I
think that there are, again, not to get too out in space here, but this is what I try
to tell the residents to get them excited. We're biologists, basically functional
biologists. There are three main drivers of evolution in my mind. One is sort of
food, you got to eat. One is reproduction, say no more. And then one is host
And host defense comes from defending yourself from predatory animals like
sabretooth cats. You got to be able to run, and you've got to be able to see your
environment. But you also need to defend yourself against bugs and pathogens.
And so no self-respecting, multicellular organism only has one way of fighting
off a bug. But when things go wrong, either genetically or in our clinic, it's
usually not everything gone wrong.
It's usually one or maybe just a couple things. And so I think that helps explain
why we seem to get away with blocking specific things. And the side effects we
see from blocking what we thought were just these linchpin cytokines or
mediators, we get away with it. And this is why you turn on your TV and you see
all these commercials for TNF blockers. Psoriasis is practically a solved problem
now because there's all these different targeted therapies.
Now, do these therapies have side effects? Of course. Are those side effects as
bad as steroids? No. We're using them in place of steroids because they're much
more well tolerated, they're less immunosuppressive, and they have fewer off
target effects. Now of course we're still learning about all of them. And they're
coming, the pipeline is just dropping new drugs constantly.
So that's a challenge for everyone. And one of the reasons that I think that a
working knowledge of immunology is certainly fundamental for my specialty,
but I think actually unfortunately a working knowledge of immunology is going
to become really an essential piece of every part of medical training because
every doctor uses steroids right now, and every doctor knows they probably
could do better.
And so what are they going to do better with? Well, it depends on the disease.
And that means you've got to know that the IL 4 and IL 13 signaling pathway
converges on the same receptor, and there's a drug for that now. And it works
great in atopic disease. So I think we get away with it because these drugs are
targeted, and because the immune system does things redundantly, otherwise
we wouldn't have evolved.
John Williams: So we're all pediatricians, we take care of human patients, of children. But with
your research you have worked both with doing human research and in animal
models. So could you talk a little bit about what you learned from each of those
and why you use both?
Scott Canna: Absolutely. So obviously, as I said before, every experiment we do, we try to
make it clinically relevant. But there's just so many really important questions
that can't be asked in people, for obvious logistical or ethical reasons. And so if
you want to know if blocking pathway X is effective in this patient population,
that is a very large undertaking in people.
You have to put together a big enough cohort, you have to get regulatory
approval, you have to have the safety information about the drug. That's to do
one experiment that may or may not work. And so we use model systems, not
only animals, but cell lines, as the best systems that we can that are the least
invasive. And of course we do everything under the supervision of our code and
as humanely as possible.
But if you want to answer some of these questions so that you can move on,
these model systems give you a way of not just doing that experiment, but also
looking at why and how things are happening. Because maybe you thought drug
X was going to work great and it didn't. And now you can interrogate that
system and you can look at what cells were there? I thought it was going to be
this big TREG expansion, but now there's all these TH 17 cells, or we have tools
to interrogate this.
And the other part is that I've made a lot about talking and studying humans
with genetic mutations. And I maintain that that is incredibly valuable. But
especially in model systems and especially in mice, there are genetic tools far
beyond what you could ever find in people, and in a much more controlled way
so you can actually learn something. And so taking advantage of some of those
genetic tools is a huge sort of leap forward.
And then finally, there's just so much complexity to these inflammatory and
immunologic systems that trying to boil everything down to a Petri dish, you're
just missing too many variables. So it's really important, at least for the work we
do, to be able to study a whole organism. Because a lot of our outcomes in our
studies are kind of clinical outcomes. We have a CBC machine in my lab. We do
blood counts in our animals all the time. Find out, did we improve their anemia?
Or did we, things like that.
Steph Dewar: This has been fascinating, as somebody who remembers a bit about
immunology from oh, so long ago. It is amazing how much we continue to learn.
And obviously there's still a lot for us to learn out there. I really appreciate you
explaining a lot of this to us. It gave me a little bit of tense remembrances back
to medical school. But this has been illuminating.
Scott Canna: So you're going to open up your immunology text tonight.
Steph Dewar: I might.
John Williams: Well, and it's really fascinating because I think it's one of the areas of clinical
medicine that we practice, like you, Steph. I remember when basically all we
had was steroids. And then we started using IVIG as the steroid of the 90's.
Right? It was called that, steroid of the 90's, because it was good for every
inflammatory disease except for those that it wasn't. And so it's really been
remarkable to see in our career, these much more specific targeted tools and
treatments become available through this really sort of basic work.
Scott Canna: And I mean, if you're paying attention, basically the most recent Nobel Prize was
for cancer immunotherapy. And that's basically awarding the cancer doctors for
discovering that the immune system was there and was probably pretty good
for treating cancer, which people like to malice and have been trumpeting for
decades. And it turns out, yeah, this is a really big deal.
So I think as we alluded to at the very beginning, inflammation is important in
every disease process. And so whether you like it or not, if you're treating
patients, you're manipulating their immune system. And because we have all
these tools, you're going to have patients in your clinic, whether you're treating
them or not, that are on drugs you've never heard of, and using mechanisms
that you're going to have to go back to your text. So it's what I call a living
knowledge. You have to have just sort of this living appreciation, and this
includes me. I mean, I Google image search pathways 10 times a day because I
forgot how SRC signals, or what is six phosphorylate again?
Steph Dewar: So thanks so much for joining us. I really appreciate you taking the time to chat
with us today.
Scott Canna: Thanks for having me.
John Williams: Scott, it's been a pleasure to have you. Thanks to everyone for listening, and
we'll speak to you next time on That's Pediatrics.
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to make a donation online.